Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Net Cash Flow: 2020-2024

Historic Net Cash Flow for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to -$4.9 million.

  • Taysha Gene Therapies' Net Cash Flow fell 2.40% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.7 million, marking a year-over-year increase of 2207.38%. This contributed to the annual value of -$4.9 million for FY2024, which is 108.75% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Net Cash Flow of -$4.9 million as of FY2024, which was down 108.75% from $56.0 million recorded in FY2023.
  • Taysha Gene Therapies' Net Cash Flow's 5-year high stood at $251.3 million during FY2020, with a 5-year trough of -$99.5 million in FY2021.
  • Over the past 3 years, Taysha Gene Therapies' median Net Cash Flow value was -$4.9 million (recorded in 2024), while the average stood at -$3.4 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first tumbled by 139.61% in 2021, then skyrocketed by 191.51% in 2023.
  • Yearly analysis of 5 years shows Taysha Gene Therapies' Net Cash Flow stood at $251.3 million in 2020, then tumbled by 139.61% to -$99.5 million in 2021, then skyrocketed by 38.48% to -$61.2 million in 2022, then surged by 191.51% to $56.0 million in 2023, then plummeted by 108.75% to -$4.9 million in 2024.